Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 5, 2014 (12 years ago)

Carbidopa and Levodopa Tablets USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet/Capsule Specifications: Teva is recalling one lot of Carbidopa and Levodopa Tablets USP, 25mg/100mg due to the potential for superpotent tablets.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Carbidopa and Levodopa Tablets USP, 25mg/100mg, 1000 count bottle, Rx only, Manufactured in Israel by Teva Pharmaceutical IND, LTD., Jeruselem, Israel, for Teva Pharmaceuticals USA, Sellersville, PA, NDC 0093-0293-10

Affected NDC 0093-0293-10

Compare with the code on your package — it is the most precise check available.

Drug: Levodopa

Recalling firm
Teva Pharmaceuticals USA
NDC code
0093-0293-10
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1538-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levodopa recalls

See all
Class II · Moderate risk

Carbidopa

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).

Ongoing Labeling / mix-up Rising Pharma Holding, Inc. NDC 16571-691-01 D-0029-2026
Class II · Moderate risk

Carbidopa and Levodopa Tablets

Packaging defect: observed packaging defect, blister packaging inadequately sealed.

Terminated Packaging defect The Harvard Drug Group NDC 0904-7257-61 D-0432-2023
Class II · Moderate risk

Duopa (carbidopa and levodopa enteral suspension)

Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassettes nearing the end of their refrigerated shelf-life

Terminated Stability / shelf life AbbVie Inc. NDC 0074-3012-07 D-0495-2017

Other recalls by Teva Pharmaceuticals USA

All 2014 recalls